Diagnovus

Diagnovus, LLC was a molecular diagnostics company focused on delivering personalized genetic information to physicians, particularly for patients with aggressive, underserved, and rare diseases. Founded in 2011 in Nashville, Tennessee, the company was established by Dr. James Stover in collaboration with two venture funds, Limestone Fund and TriStar Technology Ventures. Dr. Stover, who served as President, brought a background in medicinal chemistry from the Scripps Research Institute and experience as a life science analyst, which was foundational to the company's mission.

The company's business model was centered on in-licensing, developing, and commercializing diagnostic assays from research institutions. These products were designed to provide patient-specific genetic information to improve disease management and guide medication prescriptions. Its client base primarily consisted of physicians, pathologists, payers, and patients. Diagnovus developed and marketed a suite of tests utilizing technologies like PCR, next-generation sequencing, and gene expression analysis. Notable products included a pharmacogenetic test using a buccal swab to analyze an individual's likely response to certain medications, a PCR-based test for Barrett's esophageal cancer risk, and a gene expression test for eosinophilic esophagitis.

After securing approximately $2.3 million in capital from investors including Launch Tennessee, Mountain Group Partners, and TriStar Health Partners, the company began to generate revenue. On January 6, 2015, Diagnovus was acquired by Aegis Sciences Corporation, a toxicology and healthcare laboratory services company. The acquisition allowed Aegis to integrate Diagnovus' molecular diagnostic services, aiming to reach a broader patient population with these specialized tests. Following the acquisition, Dr. Stover transitioned to a role as vice president within Aegis' life-science business unit. Keywords: molecular diagnostics, personalized medicine, rare diseases, pharmacogenetics, diagnostic assays, genetic testing, oncology diagnostics, gastroenterology tests, next-generation sequencing, PCR testing, James Stover, Aegis Sciences Corporation, TriStar Technology Ventures, Limestone Fund, Nashville life sciences, clinical diagnostics, cancer risk test, eosinophilic esophagitis, buccal swab test, diagnostic laboratory